Atara Biotherapeutics
ATRA
37 hedge funds and large institutions have $27M invested in Atara Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
94% more capital invested
Capital invested by funds: $13.9M → $27M (+$13.1M)
16% more funds holding
Funds holding: 32 → 37 (+5)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
3.44% less ownership
Funds ownership: 30.25% → 26.81% (-3.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$845K |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$475K |
| 3 |
Jane Street
New York
|
+$254K |
| 4 |
Morgan Stanley
New York
|
+$242K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$197K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$726K |
| 2 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
-$288K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$178K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$101K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
-$31K |
ATRA Hedge Fund Activity: Q3 2025 in Review
37 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2025, worth a combined $27M — up 94% from $13.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ATRA positions and 4 closed out — a net gain of 5 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Marshall Wace, adding an estimated $845K. The largest seller was Vestal Point Capital, exiting entirely with an estimated $726K sold.
- 37 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2025, up from 32 in Q2 2025.
- Funds reported $27M of Atara Biotherapeutics stock for Q3 2025, up 94% quarter-over-quarter.
- 9 funds opened new Atara Biotherapeutics positions in Q3 2025 and 4 closed out, a net change of +5 holders.
- The largest Atara Biotherapeutics buyer in Q3 2025 was Marshall Wace, an estimated $845K added.
- The largest Atara Biotherapeutics seller in Q3 2025 was Vestal Point Capital, an estimated $726K sold.
Based on aggregated 13F filings for Q3 2025.